Download Resume - Drew Watson

DREW WATSON, Ph.D., MBA
1950 Noel Drive, Los Altos, California 94024
(650) 888-7302
[email protected]
DrewWatson.com
EXPERIENCE
Senior VP, Biostatistics, Data Management & Medical Operations
Genomic Health, Inc.
February 2003 - Present
Redwood City, California
Genomic Health, Inc. is an oncology-based health care services company providing individualized genomic analysis of tumor
biopsies. Management responsibilities include supervision of a group of 20 statisticians and data managers with direct
reporting relationship to the Executive VP of Research and Development. Clinical responsibilities include oversight of
biostatistical data management, and medical operations activities related to the design, analysis, and regulatory submission of
large-scale oncology trials in support of the development of clinical genomic tests and predictive algorithms. Non-clinical
activities include the development, validation and commercialization of high-throughput assays utilizing RNA extracted from
fixed paraffin embedded tissues.
Founder & Chief Executive Officer
Novation Biosciences (acquired by Agilent Technologies)
June 2001 - Present
San Mateo, California
Founder and CEO of a computational biology company aimed at lead drug discovery and quality control of high-throughput
biological systems. Raised $1.6M in Series A financing from investors including Accenture Venture Capital, Mobius Venture
Capital (formerly Softbank Venture Capital), GameChange LLC, and Evercore. Acted as Chief Scientific Officer responsible
for the scientific development of the Company’s primary products including
Qualifier™ - a quality/performance management system for high-throughput biological systems.
Curator™ a biological text mining solution for drug discovery.
Predictor™ - a lead discovery platform that utilizes both proprietary numerical, structural and semantic (text) data to
predict key characteristics of lead compounds.
VP of Quantitative Biology & General Manager of Incyte Microarray Systems
Incyte Genomics
1997–2001
Palo Alto, California
As General Manager, provided leadership, vision, strategic direction and operational excellence in running a division of 150
employees involved in the commercialization of gene and protein expression technologies. Also responsible for corporate
development activities including strategic and business management, technology assessment, licensing, intellectual property,
and M&A activities. Handled staffing, planning, operations, marketing and customer support activities with direct P&L
responsibility for a $20M organization. As VP of Quantitative Biology provided guidance in the development of statistical,
bioinformatics and quantitative methods for target identification and the analysis of genomic sequence and expression data.
Associate Director, Biostatistics
Chiron Corporation (acquired by Norvartis)

1994–1997
Emeryville, California
Managed a biostatistical and data management department responsible for providing leadership in the discovery,
development, manufacture and marketing of biopharmaceutical products including vaccines, therapeutics and molecular
diagnostic devices. Clinical support responsibilities at Chiron included overseeing statistical and clinical data management
activities and personnel as well as development of analysis plans, study workbooks and summary reports for the successful
submission of FDA IND, NDA, 510(k) and PMA applications. Non-clinical responsibilities involved providing biostatistical
support to drug discovery, computational chemistry, bioinformatics, clinical research, assay development, process
development, pharmacology, manufacturing, regulatory affairs, marketing, corporate compliance and quality assurance.

1950 Noel Drive, Los Altos, California 94024
(650) 888-7302
[email protected]
www.DrewWatson.com
Drew Watson, Ph.D., MBA
Manager, Experimental Statistics
Syntex Pharmaceuticals (acquired by Roche Biosciences)

Provided management and statistical expertise for pharmaceutical research activities. Instrumental in the establishment of an
Experimental Statistics Department responsible for R&D, pharmaceutical research, clinical development, pharmacology and
assay development activities. Responsibilities included the application of statistical experimental design, optimization,
robustness, reliability and statistical quality control methods for process improvement.
Founder & Principal Management Consultant
Process Plus, Inc.

1985–1992
Los Altos, California
Founder and principal management consultant for Process Plus Inc. - a management consulting firm. Obtained over ten
years’ management experience under the guidance of the late late Dr. W. Edwards Deming - “Father of the Japanese
Industrial Revolution.” Consulted to industries as diverse as aerospace, biotechnology, electronics, biopharmaceutical and
health care. Clients included Hewlett-Packard (nine divisions), Dow Chemical, Applied Materials, NEC, Intel, 3-Com, Siltec,
Printed Circuit Builders, Computer Products Inc., Connector Technology Inc., Conejo Circuits and Armstrong World
Industries.
Senior Statistician
Hewlett-Packard Corporation

1992–1994
Palo Alto, California
1980–1985
Palo Alto, California
Provided management and statistical support to nine divisions, including the printed circuit and personal computer divisions.
Supported several other divisions, including the HP-3000, instrumentation and medical products divisions. Introduced
Hewlett-Packard's first quality improvement program based on the philosophies of Dr. W. Edwards Deming. Implemented
Hewlett-Packards first just-in-time manufacturing system.
EDUCATION
1998
Golden Gate University, Los Altos, California
MBA; G.P.A. – 4.0
1990
University of California, Los Angeles, California
Ph.D., Biostatistics – Advisor: Robert Elashoff, Ph.D.; G.P.A. – 3.8
1984
Stanford University, Stanford, California
M.S., Computational Statistics – Advisor: Jerome Friedman, Ph.D.; G.P.A. 3.5
1980
California State University, Hayward, California
B.S., Statistics; G.P.A. – 3.5
AWARDS & RECOGNITION
1990
UCLA, School of Public Health, Los Angeles, California
Ruth F. Richards Award for outstanding academic achievement, character, leadership, extracurricular
involvement and service to the community.
1988
California State Superior Court, Santa Clara, California
Recognized as an expert witness in the fields of statistics and statistical quality control.
1981
Stanford University, Department of Statistics, Stanford, California
Honors Cooperative Program: Selected by Stanford University and Hewlett-Packard Corporation to pursue
graduate education at Stanford University.
1978
Lawrence Livermore National Laboratory (LLNL), Livermore, California
Student internship in mathematical statistics.
1950 Noel Drive, Los Altos, California 94024
(650) 888-7302
[email protected]
www.DrewWatson.com
PAGE 2 OF 5
Drew Watson, Ph.D., MBA
PUBLICATIONS
Cronin M., Sangli C., Liu ML, Pho M., Dutta D., Nguyen A., Jeong J., Wu J., Langone K., Watson D.,
Analytical Validation of the Oncotype DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response
Prediction in Node-Negative, Estrogen Receptor–Positive Breast Cancer, Paper accepted for publication, Clinical
Chemistry.
Mina L, Soule SE, Badve S, Baehner FL, Baker J, Cronin M, Watson D, Liu ML, Sledge GW Jr, Shak S, Miller KD.,
Predicting Response To Primary Chemotherapy: Gene Expression Profiling Of Paraffin-Embedded Core Biopsy Tissue,
Breast Cancer Research Treat. (Published ahead of print Oct 13, 2006).
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr,
Wickerham DL, Wolmark N., Gene Expression And Benefit Of Chemotherapy In Women With Node-Negative,
Estrogen Receptor-Positive Breast Cancer. Journal of Clinical Oncology. 2006 Aug 10;24(23):3726-34.
Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, Blick NT,
Greenberg D, Fehrenbacher L, Langholz B, Quesenberry CP. A Population-Based Study Of Tumor Gene Expression
And Risk Of Breast Cancer Death Among Lymph Node-Negative Patients., Breast Cancer Research. 2006;8(3).
Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P,
Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S., Gene Expression Profiles In Paraffin-Embedded
Core Biopsy Tissue Predict Response To Chemotherapy In Women With Locally Advanced Breast Cancer. Journal of
Clinical Oncology. 2005 Oct 10;23(29):7265-77.
Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi
GN., Prognostic Role Of A Multigene Reverse Transcriptase-PCR Assay In Patients With Node-Negative Breast Cancer
Not Receiving Adjuvant Systemic Therapy. Clinical Cancer Research. 2005 May 1;11(9):3315-9.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER,
Wickerham DL, Bryant J, Wolmark N., A Multigene Assay To Predict Recurrence Of Tamoxifen-Treated, Node-Negative
Breast Cancer., New England Journal of Medicine. 2004 Dec 30;351(27):2817-26.
Evertsz E., Gupta R., Starink P. & Watson D., Technology and Applications of Gene Expression Microarrays, Microarray
Biochip Technology, BioTechniques Book Division, Eaton Publishing, Natick, Massachusetts, 2000.
Watson G. and Minor J., Statistical Methods for Molecular Diagnostics, Proceedings of the Biopharmaceutical Section,
American Statistical Association, 1997.
Minor J., Namini H. & Watson G., Generalized Ridge Analysis with Application to Population Pharmacokinetics/
Dynamics, Journal of Biopharmaceutical Statistics, 6(1), 105-114, 1996.
Watson G. and Dahl T., Analysis of the Stability Properties of Drug Formulation Through the Use of Neural Networks,
Proceedings of the Biopharmaceutical Section, American Statistical Association, 68-73, 1993.
Watson G. and Elashof R., Nonparametric Influence Diagnostics for the Survivor Function, Technical Report, Department
of Biomathematics, University of California, Los Angeles, CA, 1990.
Watson G., Influential Observations in Survival Models with Censored Data, Technical Report, Department of
Biomathematics, University of California, Los Angeles, CA, 1990.
1950 Noel Drive, Los Altos, California 94024
(650) 888-7302
[email protected]
www.DrewWatson.com
PAGE 3 OF 5
Drew Watson, Ph.D., MBA
POSTERS & PRESENTATIONS
Watson D, Palmer G, Baker J, Shak S., The Impact on the Recurrence Score Due to Patient Variation in the Quantitative
Expression of Individual Genes or Gene Groups, Presented at: 29th Annual San Antonio Breast Cancer Symposium.
December 14-17, 2006. San Antonio, TX. Abstract #6039.
Kim C, Tang G, Baehner FL, Watson D, Costantino JP, Paik S, Shak S, Wolmark N., A Comparison of Estrogen Receptor
(ER) Measurement by Three Methods in Node-Negative, Estrogen Receptor (ER)-Positive Breast Cancer: Ligand Binding
(LB), Immunohistochemistry (IHC), and Quantitative RT-PCR., Presented at: 29th Annual San Antonio Breast Cancer
Symposium. December 14-17, 2006. San Antonio, TX. Abstract #3116
Shak S, Baehner FL, Palmer G, Ballard JT, Baker J, Watson D., Relationship Between Proliferation Genes and Expression of
Hormone and Growth Factor Receptors: Quantitative RT-PCR In 10,618 Breast Cancers. Presented at: 29th Annual San
Antonio Breast Cancer Symposium. December 14-17, 2006. San Antonio, TX. Abstract #6111.
Shak S, Baehner FL, Palmer G, Ballard JT, Baker J, Watson D., Subtypes of Breast Cancer Defined by Standardized
Quantitative RT-PCR Analysis of 10,618 Tumors, Presented at: 29th Annual San Antonio Breast Cancer Symposium.
December 14-17, 2006. San Antonio, TX. Abstract #6118.
Baehner FL, Habel LA, Quesenberry CP, Capra A, Tang G, Paik S, Wolmark N, Watson D, Shak S., Quantitative RT-PCR
Analysis of ER and PR by Oncotype DX Indicates Distinct and Different Associations With Prognosis and Prediction of
Tamoxifen Benefit, Presented at: 29th Annual San Antonio Breast Cancer Symposium. December 14-17, 2006. San
Antonio, TX. Abstract #45.
Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Clark K, Watson D., Analytical Validation For The
Oncotype DX Breast Cancer Assay, a High Complexity, Multi-Analyte Molecular Diagnostic Test Service, Presented at:
Association for Molecular Pathology 2006 Annual Meeting. November 16-19, 2006. Orlando, Florida. Poster #ST23.
O'Connell MJ, Paik S, Yothers G, Costantino JP, Cowens JW, Clark KM, Baker J, Hackett J, Watson D, Wolmark N.,
Relationship Between Tumor Gene Expression and Recurrence in Stage II/III Colon Cancer: Quantitative RT-PCR Assay
Of 757 Genes in Fixed Paraffin-Embedded (FPE) Tissue, Presented at: 42nd Annual Meeting of the American Society of
Clinical Oncology. June 2-6, 2006, Atlanta, GA. Abstract #3518.
Bitterman P, Watson D, Cronin M, Mosquera JM, Cobleigh M, Baehner R, Shak S, Baker J, Comparison Of ER, PR, HER2,
And Ki-67 Quantitative Expression in Formalin-Fixed, Paraffin-Embedded Breast Carcinomas by RT-PCR with Protein
Expression By Immunohistochemistry, Presented at: United States and Canadian Academy of Pathology Annual Meeting.
March 6 - 12, 2004. Vancouver, British Columbia. Abstract #83.
Cronin M, Watson D, Dutta D, Liu ML, Pho M, Baehner R, Esteban J, Baker J, Shak S, Reproducibility of Quantitative
Gene Expression Analysis by a New RT-PCR Assay Using Fixed Paraffin-Embedded Tissues: A Molecular Tomographic
Scanning Study, Presented at: United States and Canadian Academy of Pathology Annual Meeting. March 6 - 12, 2004.
Vancouver, British Columbia. Abstract #1491.
Mamounas E, Tang G, Bryant J, Paik S, Shak S, Costantino J, Watson D, Wickerham DL, Wolmark N., Association Between
the 21-Gene Recurrence Score Assay (RS) and Risk of Loco-Regional Failure in Node-Negative, ER-Positive Breast
Cancer: Results From NSABP B-14 and NSABP B-20, Presented at: 28th Annual San Antonio Breast Cancer Symposium.
December 8-11, 2005. San Antonio, TX. Abstract #29.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner R, Walker M, Watson D, Bryant J, Wolmark N., Risk
Classification of Breast Cancer Patients by the Recurrence Score Assay: Comparison to Guidelines Based On Patient Age,
Tumor Size, and Tumor Grade, Presented at: 27th Annual San Antonio Breast Cancer Symposium. December 8-11, 2004.
San Antonio, TX. Abstract #104.
Future Trends for Bioinformatics Companies, Kellogg Biotechnology Conference, Sponsored by the Kellogg School of
Management, Northwestern University, April 2001.
cDNA Based Microarray Technology and Performance, Research Presentation, FDA/Industry Workshop on Microarray
Technology, Sponsored by the Bay Area Biosciences Center, Stanford University, CA, May 17th, 2000.
Data Mining in the Genomics Revolution, Keynote Speaker, American Statistical Association Spring 2000 Conference,
Sponsored by the American Statistical Association, Wilmington, DE, April 28th, 2000.
Statistical Methods for Molecular Diagnostics, Invited Speaker, Joint Meetings of the American Statistical Association,
Anaheim, CA, August 11th, 1997.
Strategies of Research, Invited Speaker, Genentech Inc., Sponsored by the San Francisco Chapter of the American
Statistical Association, San Francisco, CA, April, 1995.
1950 Noel Drive, Los Altos, California 94024
(650) 888-7302
[email protected]
www.DrewWatson.com
PAGE 4 OF 5
Drew Watson, Ph.D., MBA
PATENTS
US Patent : Tissue Specific Genes of Diagnostic Import.
US Patent Application 60/375,251: Microarray Performance Management System.
U.S. Provisional patent Application Serial No. 60/810,077: Gene Expression Markers for Colorectal Cancer
COMPUTER SKILLS
Packages:
SAS, S-Plus, R, BMDP, SPSS, IMSL, GAUSS, LISP-Stat, GLIM, Mathematica, BMDS, StatXact, LogXact,
Egret, East, ECHIP, Design-Ease, Statistica, SAS JMP, Resampling Stats, Maple, CART, MARS, Minitab,
Spotfire
Languages: FORTRAN, C/C++, Visual Basic, SQL
Operating Systems: VAX/VMS, UNIX, MS-DOS, Mac, Windows
SECURITY CLEARANCES
Department of Energy (D.O.E) “Q” (currently inactive).
1950 Noel Drive, Los Altos, California 94024
(650) 888-7302
[email protected]
www.DrewWatson.com
PAGE 5 OF 5